Analysts Issue Forecasts for Eloxx Pharmaceuticals’ Q2 2019 Earnings (OTCMKTS:ELOX)

Eloxx Pharmaceuticals (OTCMKTS:ELOX) – Investment analysts at SunTrust Banks issued their Q2 2019 earnings estimates for shares of Eloxx Pharmaceuticals in a note issued to investors on Wednesday, June 19th. SunTrust Banks analyst J. Lee expects that the company will post earnings per share of ($0.40) for the quarter. SunTrust Banks also issued estimates for Eloxx Pharmaceuticals’ Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.64) EPS, FY2020 earnings at ($1.41) EPS, FY2021 earnings at ($1.45) EPS, FY2022 earnings at ($1.32) EPS and FY2023 earnings at ($0.92) EPS.

Several other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Eloxx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 13th. Canaccord Genuity restated a “buy” rating and set a $17.00 price target (down previously from $20.00) on shares of Eloxx Pharmaceuticals in a report on Wednesday, May 15th. They noted that the move was a valuation call.

Shares of OTCMKTS:ELOX opened at $9.58 on Monday. The company’s 50 day moving average is $10.06. Eloxx Pharmaceuticals has a 12-month low of $8.49 and a 12-month high of $20.40.

Eloxx Pharmaceuticals (OTCMKTS:ELOX) last issued its earnings results on Thursday, May 9th. The company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.08.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in Eloxx Pharmaceuticals by 36.9% during the fourth quarter. BlackRock Inc. now owns 1,493,471 shares of the company’s stock valued at $17,938,000 after acquiring an additional 402,501 shares in the last quarter. Geode Capital Management LLC boosted its stake in Eloxx Pharmaceuticals by 10.0% during the fourth quarter. Geode Capital Management LLC now owns 237,986 shares of the company’s stock worth $2,858,000 after buying an additional 21,634 shares during the last quarter. Bank of America Corp DE raised its position in Eloxx Pharmaceuticals by 226.0% in the fourth quarter. Bank of America Corp DE now owns 14,209 shares of the company’s stock valued at $171,000 after purchasing an additional 9,851 shares during the period. Rhumbline Advisers raised its position in Eloxx Pharmaceuticals by 51.5% in the fourth quarter. Rhumbline Advisers now owns 28,562 shares of the company’s stock valued at $343,000 after purchasing an additional 9,707 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in Eloxx Pharmaceuticals by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 10,172 shares of the company’s stock valued at $122,000 after purchasing an additional 7,944 shares during the period.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.

Further Reading: Dow Jones Industrial Average (DJIA)

Earnings History and Estimates for Eloxx Pharmaceuticals (OTCMKTS:ELOX)

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.